{
    "organizations": [],
    "uuid": "038939753d0ff9b84fd6008ea211f0c9a93904ec",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-rexahn-says-phase-2a-trial-of-trea/brief-rexahn-says-phase-2a-trial-of-treatment-for-type-of-pancreatic-cancer-advances-to-second-stage-idUSFWN1SM10A",
    "ord_in_thread": 0,
    "title": "BRIEF-Rexahn Says Phase 2a Trial Of Treatment For Type Of Pancreatic Cancer Advances To Second Stage",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Rexahn Pharmaceuticals Inc:\n* REXAHN PHASE 2A COMBINATION STUDY OF RX-3117 AND ABRAXANEÂ® IN FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS ADVANCES TO SECOND STAGE\n* REXAHN PHARMACEUTICALS INC - SMC HAS CONFIRMED THAT COMBINATION OF RX-3117 AND ABRAXANE IS SAFE AND WELL TOLERATED Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T20:24:00.000+03:00",
    "crawled": "2018-05-16T18:56:46.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "rexahn",
        "pharmaceutical",
        "inc",
        "rexahn",
        "phase",
        "2a",
        "combination",
        "study",
        "metastatic",
        "pancreatic",
        "cancer",
        "patient",
        "advance",
        "second",
        "stage",
        "rexahn",
        "pharmaceutical",
        "inc",
        "smc",
        "confirmed",
        "combination",
        "abraxane",
        "safe",
        "well",
        "tolerated",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}